Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study

Figure 2

Reference ranges: haemoglobin 130-170 g/L (for males) and 120-150 g/L (for females), platelet count 150-400 109/L, albumin 35-50 g/L, and C-reactive protein 0-7.5 mg/L.